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Progesterone is a critical regulator of normal female reproductive function, with diverse tissue-specific effects
in the human.The effects of progesterone are mediated by its nuclear receptor (PR) that is expressed as two
isoforms, PRA and PRB, which are virtually identical except that PRA lacks 164 amino acids that are present
at the N-terminus of PRB. Considerable in vitro evidence suggests that the two PRs are functionally distinct
and in animals, tissue-specific distribution patterns of PRA and PRB may account for some of the diversity
of progesterone effects. In the human, PRA and PRB are equivalently expressed in most target cells, suggesting
that alternative mechanisms control the diversity of progesterone actions. PR mediates the effects of
progesterone by association with a range of coregulatory proteins and binding to specific target sequences
in progesterone-regulated gene promoters. Ligand activation of PR results in redistribution into discrete
subnuclear foci that are detectable by immunofluorescence, probably representing aggregates of multiple
transcriptionally active PR-coregulator complexes. PR foci are aberrant in cancers, suggesting that the
coregulator composition and number of complexes is altered. A large family of coregulators is now described
and the range of proteins known to bind PR exceeds the complement required for transcriptional activation,
suggesting that in the human, tissue-specific coregulator expression may modulate progesterone response.
In this review, we examine the role of nuclear localization of PR, coregulator association and tissue-specific
expression in modulating progesterone action in the human.
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Introduction
Progesterone is an essential regulator of normal human
female reproductive function in the uterus, ovary,
mammary gland and brain, and also plays an important
role in non-reproductive tissues such as the
cardiovascular system, bone and the central nervous
system, highlighting the widespread role of this hormone
in normal physiology [Graham and Clarke, 1997; Graham
and Clarke, 2002; Li et al., 2004; Mote et al., 2007].The
effects of progesterone are mediated through the nuclear
progesterone receptor (PR), which interacts with
transcriptional coregulators [Lonard and O'Malley, 2007],
moves into nuclear aggregates [Arnett-Mansfield et al.,
2004; Arnett-Mansfield et al., 2007] and regulates gene
expression. Although progesterone plays a pivotal role
in normal physiology, exposure to its analogues in
exogenous hormone formulations is associated with
deleterious effects, most notably an increase in breast
cancer risk [Beral, 2003; Holtorf, 2009; Horwitz, 2008;
Lee et al., 2005; Pike et al., 2007; Rossouw et al., 2002;
Santen, 2003]. Given the diverse roles of progesterone
in normal tissues and in cancer, developing a detailed
understanding of the mechanisms that direct its cell and
tissue specificity is a high priority.This review will explore
the role of nuclear localization of PR, its association with
coregulators, and coregulator complement of target
tissues as critical contributors to the selectivity and
specificity of progesterone effects in normal and malignant
target tissues.
The progesterone receptor
Progesterone effects are mediated by binding to the
nuclear progesterone receptor (PR). PR is a member of
a large family of ligand-activated nuclear transcription
regulators [Escriva et al., 2004; Evans, 1988; McEwan,
2009], which are characterised by organisation into
specific functional domains and are conserved, to differing
degrees, between species and family members. PR is
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carboxyl-terminal ligand-binding domain (LBD). In
addition, the receptor contains multiple activation (AF)
and inhibitory (IF) function elements, which enhance and
repress transcriptional activation of PR by association of
these regions with transcriptional coregulators [Edwards,
2000; Huse et al., 1998; McEwan, 2009; McKenna et al.,
1999; McKenna and O'Malley, 2002; Sartorius et al.,
1994;Vegeto et al., 1993]. Newly-transcribed cytoplasmic
PR is assembled in an inactive multi-protein chaperone
complex [Smith et al., 1990], which is essential for
maintenance of the inactive receptor in a state that is
competent to bind ligand [Pratt et al., 2004]. Progestin
binding to PR causes a conformational change leading
to dissociation of chaperones, dimerization, binding to
progestin response elements in the promoters of target
genes and recruitment of specific coactivators and general
transcription factors, resulting in modulation of
transcription of those genes [Beato et al., 1987;
Gronemeyer, 1991;Tata, 2002].
In addition to the ligand-activated transcriptional effects
discussed above, which reflect the nuclear activity of this
receptor, PR also regulates transcription via non-genomic
pathways such as activation of second messenger
signaling cascades [Lange et al., 1998; Leonhardt et al.,
2003; Nilsen and Brinton, 2002; Nilsen and Brinton, 2003].
Ligand-independent activation of PR can occur in a
cell-type and promoter-specific manner and provides
evidence for regulation of PR via cytoplasmic and
membrane generated signals [Daniel et al., 2007;
Jacobsen et al., 2005].The molecular mechanisms of PR
action through non-genomic mechanisms, including
receptor cross-talk with growth factor signaling pathways,
have been reviewed in detail recently [Lange, 2008a;
Lange, 2008b], and this review will not explore these
issues further.
Progesterone action is mediated by two
PR isoforms
In the human, the effects of progesterone are mediated
by two distinct forms of the PR transcribed from a single
gene by alternate initiation of transcription from two
distinct promoters [Gronemeyer et al., 1991; Kastner et
al., 1990], giving rise to transcripts encoding two protein
isoforms, PRA and PRB. PRA and PRB are identical in
sequence, except that PRA lacks 164 amino acids at the
N-terminus, making it the shorter of the two proteins
[Kastner et al., 1990].
Considerable evidence from transient cotransfection
studies into a variety of cell lines suggest that PRA and
PRB are functionally unique transcriptional regulators,
capable of differentially regulating gene transcription
within the same promoter context, and capable of
recognising entirely different promoters [Aupperlee and
Haslam, 2007; Brayman et al., 2006; Jacobsen et al.,
2002; Richer et al., 2002;Tung et al., 1993]. In the mouse,
ablation of PRA or PRB has revealed the unique roles
for PRA and PRB, demonstrating that PRB is required
for normal mammary gland development [Mulac-Jericevic
et al., 2003], while PRA is essential for uterine
development and reproductive function [Mulac-Jericevic
et al., 2000].
Although the precise mechanisms underlying the
differential activities of the two human PR isoforms is not
fully understood, structure-function studies suggest that
the AF3 domain located within the PRB upstream
sequence region, which is absent in PRA, [Sartorius et
al., 1994] contributes to PRB transcriptional activity by
suppressing the activity of an inhibitory domain (ID)
contained within the sequences common to PRA and
PRB [Abdel-Hafiz et al., 2002;Tung et al., 2006].
Moreover, evidence suggests that the two receptors adopt
distinct conformations within the cell [Bain et al., 2000;
Bain et al., 2001] allowing PRA to interact with a set of
coregulators that are different from those which interact
with PRB [Tetel et al., 1999].This is supported by studies
demonstrating that PRA has a higher affinity for the
corepressor SMRT than PRB in the presence of PR
antagonists, and PRA does not interact directly or with
as high an affinity as PRB with the coactivators SRC-1
and SRC-2 upon agonist binding [Giangrande et al., 2000;
Heneghan et al., 2007; Molenda-Figueira et al., 2008],
potentially contributing to differences in the transcriptional
activities of the two human PR isoforms and further
enhancing the complexity of this regulatory system.
In addition to the translation start sites driving expression
of PRA and PRB, a third start site within the PR gene has
been identified at amino acid position 595 that could give
rise to a truncated PR isoform, PRC. If expressed, PRC
would lack the PR N-terminus and one zinc finger of the
DNA binding domain, rendering it transcriptionally inactive
but able to bind hormone, dimerize and localize in the
nucleus [Wei et al., 1990;Wei et al., 1996]. Although in
vitro reports have suggested that PRC may either
enhance or antagonize the activities of PRA and PRB
[Condon et al., 2006;Wei et al., 1996;Wei et al., 1997],
recent evidence suggests that PRC is not expressed in
vivo and has no real physiological role in progesterone
signaling [Samalecos and Gellersen, 2008].
Relative expression of the PR isoforms contributes
to selectivity of PR action. Much of our current
understanding of the distinct functions of PRA and PRB
derives from models where only a single PR isoform is
expressed and in which the PR homodimer is the
dominant molecular species. However, in a cell that
co-expresses both PR isoforms, there is the potential for
3 molecular species (PRB homodimers, PRA homodimers
and PRA-PRB heterodimers) to exist concurrently and to
contribute to the complexity of PR action.
In mice, where PRA and PRB are frequently expressed
in different cells within the reproductive system [Gava et
al., 2004; Mote et al., 2006], the homodimer is clearly a
critical contributor to progesterone action, consistent with
the divergent and tissue-specific roles identified for these
proteins in knockout studies [Mulac-Jericevic et al., 2003;
Mulac-Jericevic et al., 2000]. In human physiology,
however, the majority of PR positive cells express PRA
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one PR isoform are uncommon [Mote et al., 1999; Mote
et al., 2002; Mote et al., 2007].This suggests that in the
human, progesterone exerts its effects in cells that
co-express both PR isoforms, and that the PRA-PRB
heterodimer is the predominant molecular species.
It appears that the PR dimer species that predominates
within a target cell influences the transcriptional program
regulated by the receptor. For example, in vitro studies
in cell lines expressing only one PR isoform (PRA or PRB)
have demonstrated that the gene sets regulated by PRA
and PRB homodimers are largely non-overlapping and
that the number of genes uniquely regulated by PRB far
exceeds the number regulated by PRA [Richer et al.,
2002]. Interestingly, in cell lines co-expressing both PRA
and PRB, leading to the prevalence of the heterodimer,
a unique and smaller number of genes are
progesterone-regulated compared to that seen in cells
expressing only one PR isoform [Graham et al., 2005;
Richer et al., 2002]. Overall, these findings demonstrate
that the PR homodimers and the heterodimer have the
capacity to regulate different suites of genes and that the
ratio of PR isoform expression plays an important role in
influencing the transcriptional program regulated by PR
in target tissues.
The PR isoform ratio also influences the capacity of PRA
to regulate the activity of PRB. In transfection studies,
PRA has been shown to be a dominant inhibitor of the
transcriptional activity of PRB [Chalbos and Galtier, 1994;
Giangrande and McDonnell, 1999; McDonnell and
Goldman, 1994; Meyer et al., 1992;Tung et al., 1993;
Vegeto et al., 1993;Wen et al., 1994]. Furthermore, PRA
has been shown to similarly regulate the activity of a
number of nuclear receptors, including the glucocorticoid,
mineralocorticoid, androgen, and estrogen receptors
[McDonnell and Goldman, 1994;Tung et al., 1993;Vegeto
et al., 1993;Wen et al., 1994]. However, it appears that
PRA can only exert this dominant negative effect when
it is in very significant excess, as the transient transfection
experiments that demonstrated the dominant negative
inhibitory activity of PRA were likely to involve higher
levels of PRA expression than are ever observed
endogenously.
This possibility was explored through the construction of
cell lines, normally containing equivalent levels of PRA
and PRB in recapitulation of their relative levels observed
in human tissues, but in which PRA expression can be
induced to be in excess over PRB. In this model system,
induction of PRA expression to five-fold excess over PRB
had little impact on PR-regulated gene expression
[Graham et al., 2005]. In particular, the
progestin-regulated gene sets in cells expressing
equivalent levels of PRA and PRB, and in cells
over-expressing PRA, were largely overlapping [Graham
et al., 2005].This demonstrates that there is no dominant
negative effect of PRA, when PRA is in physiological
excess of PRB in cells endogenously co-expressing both
PR isoforms. Most progesterone target tissues express
both PRA and PRB at relative levels that are not vastly
different, suggesting that dominant negative inhibition of
PRB by PRA is not likely to be a prominent effect in
normal human physiology.
PR expression in target tissues
PR proteins are expressed in a variety of human tissues,
including the uterus, mammary gland, brain, pancreas,
bone, ovary, testes, and tissues of the lower urinary tract
[Bland, 2000; Graham and Clarke, 1997; Graham and
Clarke, 2002; Han et al., 2009; Ozawa, 2005;Tincello et
al., 2009].The ubiquitous expression of PR highlights the
widespread physiological effects that progesterone can
exert in a variety of organs throughout the body.
PR expression in non-human species
PRA and PRB proteins were initially demonstrated in the
chick oviduct in the early 1970s [Schrader and O'Malley,
1972; Schrader et al., 1972] and many studies have since
determined the relative levels of PRA and PRB isoforms
in a variety of species including birds, reptiles, rodents
and mammals.The majority of these early studies
examined PR isoform expression using cell-free methods
in organs associated with reproduction, and a dominant
expression of one PR isoform was frequently observed.
PRB was the dominant isoform in the oviduct of the
reproductively active freshwater painted turtle (Chrysemys
picta) [Giannoukos et al., 1995; Reese and Callard, 1989]
and also the quail [Dufrene et al., 1989], whilst the rabbit
uterus expressed only PRB [Lamb et al., 1986].
Conversely, rodent reproductive tissues expressed a
predominance of PRA [Schneider et al., 1991; Shyamala
et al., 1990]. In the mouse uterus and mammary gland
the PRA:PRB ratio was 3:1, whilst in murine vaginal tissue
it was 2:1 [Ilenchuk and Walters, 1987; Schneider et al.,
1991]. Moreover, the relative expression levels of PRA
and PRB varied in different organs within the same
species, as the liver of the painted freshwater turtle
expressed predominantly PRA, in contrast to the
PRB-predominant expression in the oviduct of the same
species [Giannoukos et al., 1995], whilst the rat brain,
unlike the rodent reproductive organs, expressed
predominantly PRB [Kato et al., 1993].These data
suggested the ratio of PRA and PRB to be both species-
and tissue-specific. Seasonal changes in the relative
expression of PRA and PRB in the turtle oviduct also
occur, implying influence by circulating ovarian steroid
hormones that fluctuate throughout the reproductive cycle
[Giannoukos et al., 1995].
The advent of antibodies with specificity for PRA or PRB
demonstrated that the predominance of one PR isoform
previously demonstrated in whole tissues by cell-free
methods was contributed in part by cell-type specificity
of PR isoform expression. For instance, the PRA
predominance of mouse uterus identified in cell-free
studies is contributed by high expression of PRA in the
myometrium and stroma, whereas PRA is absent from
luminal epithelial cells, which contain only PRB [Mote et
al., 2006]. Both PR isoforms are present in the uterine
stroma and myometrial cells, with levels that fluctuate
with cyclical systemic hormonal exposure [Mote et al.,
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cycle-related changes in PRA:PRB [Gava et al., 2004].
There is also a temporal and/or spatial separation of PRA
and PRB expression in rodent mammary epithelial cells
during normal mammary gland development [Aupperlee
et al., 2005; Kariagina et al., 2007]. In the mouse, PRA
was the predominant isoform expressed in the pubertal
and mature virgin mammary gland, whilst PRB
predominance was observed during pregnancy when
PRA and PRB rarely co-localized [Aupperlee et al., 2005].
Distinct PRA and PRB expression has also been reported
in the rat mammary gland during development [Kariagina
et al., 2007]. PRA was only expressed in luminal epithelial
cells, whilst PRB was present in both luminal and
myoepithelial cells, indicating a role for PRB in
myoepithelial cell regulation [Kariagina et al., 2007].The
cell-specificity of PR isoform expression in animal tissues
further supports the demonstration in PR isoform null
animals of distinct activities of the isoforms in the mouse,
and reflects the likelihood that progesterone action is
mediated differentially in PRB-positive cells compared to
PRA-positive cells within rodent PR-target tissues in vivo.
PR expression in the human
In contrast to the predominant expression of one PR
isoform frequently observed in animal tissues, in normal
human tissues in vivo, including the breast and uterus,
all PR+ epithelial cells co-expressed PRA and PRB at
similar levels [Mote et al., 1999; Mote et al., 2002].This
suggests that co-location and thus cooperative activity of
PRA and PRB mediates PR action in the human.This is
in contrast to the mouse, as outlined above, where the
non-overlapping expression of PRA and PRB and the
lack of co-location of the two PR isoforms, strongly
suggest the PR homodimer to be the active species
[Aupperlee et al., 2005; Mote et al., 2006]. Although PRA
and PRB proteins are normally expressed equally in
human tissues, there is some evidence for differential
hormonal regulation of the two PR isoforms in the
glandular epithelial cells of the endometrium. During the
secretory phase of the menstrual cycle, when high
circulating levels of progesterone are associated with
decreased PR expression, PRA was preferentially
decreased, resulting in a distinct predominance of PRB
in these cells at this time [Mote et al., 1999].
In contrast to the balanced expression of PRA and PRB
in normal human tissues, progression of breast and
endometrial tissues from normal to malignancy is
frequently accompanied by progressive changes in PR
isoform expression. In normal breast and in proliferative
disease without atypia of the breast, PRA and PRB are
co-expressed within the same cells in comparable
amounts [Mote et al., 2002], and there is little variation
in the cell-to-cell relative expression of PRA and PRB. In
atypical breast lesions, however, there is a significant
increase in predominant expression of PRA or PRB
[Graham et al., 1995; Mote et al., 2002]. Similarly, in
hyperplastic areas of endometrial tissue there is increased
predominance of one PR isoform, suggesting that lack
of coordinated PRA:PRB expression is an early event in
endometrial cancer [Arnett-Mansfield et al., 2001]. In
breast cancer, PR isoform predominance, especially PRA
predominance, is evident in a significant proportion of
ductal carcinomas in situ (DCIS) and invasive cancers
[Mote et al., 2002], and moreover, there is marked
heterogeneity of PRA:PRB expression between
neighbouring cells in breast cancers [Mote et al., 2002].
In endometrial cancers one PR isoform is frequently lost,
and PR isoform loss is often associated with higher
histological grade [Arnett-Mansfield et al., 2001].
In summary, studies of PR expression in both humans
and animals indicate that PRA and PRB proteins are
expressed in a species-, tissue- and cell type-specific
manner, highlighting the need for caution when
extrapolating results between species.The data suggest
that PRA and PRB are able to work both alone or together
to modulate the complex and divergent pathways of
progesterone action in normal and malignant physiology,
and that the alterations in isoform expression frequently
observed in malignancy, will affect PR dimer
predominance and thereby modulate transcriptional
response.
Nuclear positioning of PR
Both liganded and unliganded PR are located in the cell
nucleus, and localize to specific intra-nuclear locations:
when liganded, the activated PR moves into nuclear
aggregates, or 'foci', whereas unliganded PR is distributed
evenly throughout the nucleus. In human tissues,
endogenous PR is located in foci only in the secretory
phase of the menstrual cycle, when progesterone levels
are high [Arnett-Mansfield et al., 2004; Arnett-Mansfield
et al., 2007]. Ligand binding is required for PR movement
into foci [Arnett-Mansfield et al., 2004], and PR isoforms
dimerise when they move into foci [Arnett-Mansfield et
al., 2007]. PR foci are tethered to the nuclear matrix, and
both DNA binding and nuclear matrix tethering are
required for PR to move into foci [Graham et al., 2009].
Within these tethered structures PR is highly mobile,
consistent with its rapid occupancy at specific chromatin
locations associated with transcription [Graham et al.,
2009]. Ligand-bound PR in foci co-locates with nascent
RNA, activated RNAPolII, and also with the chromatin
remodeling histone acetyl transferase p300
[Arnett-Mansfield et al., 2007] and transcriptional inhibitors
inhibit the movement of PR into foci [Arnett-Mansfield et
al., 2007], demonstrating the link between PR foci and
transcriptional activity. Exposure to Roscovitine, which
inhibits recruitment of the p160 coactivator SRC-1, also
prevents ligand-dependent foci formation.These data
collectively demonstrate that foci contain multiple
activated PR-coactivator complexes associated with the
basic transcriptional machinery.
Nuclear aggregation of transcription factors, including
nuclear receptors, is commonly observed [Zaidi et al.,
2004; Zink et al., 2004], due to the structural constraints
imposed by nuclear compartmentalization, and to the
efficiency gains of co-location of functionally-related
molecules. A number of components of nuclear receptor
pathways have been shown to aggregate in the nucleus,
and transfection of tagged receptors has shown that
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receptor (AR) [Tyagi et al., 2000], glucocorticoid receptor
(GR) [van Steensel et al., 1995] and mineralocorticoid
receptor (MR) [Fejes-Toth et al., 1998] form nuclear
aggregates when exposed to ligand [Fejes-Toth et al.,
1998; Htun et al., 1996; Htun et al., 1999;Tyagi et al.,
2000]. Furthermore, various nuclear receptor-associated
proteins are located in discrete domains [Baumann et al.,
2001; Guo et al., 2000] such as p53, steroid receptor
coactivator (SRC), and glucocorticoid receptor interacting
protein1 (GRIP1), which localize in the PML nuclear body.
The frequent observation of nuclear aggregation of
nuclear receptor components supports the view that PR
foci identified in human tissues are transcriptional
complexes required for progesterone action.
PR moves into different foci in cancer cells and
normal cells. While PR foci are detected in both normal
human tissues and in cancers, they are different. PR foci
in normal endometrium have a median length of 0.65 µm,
but are significantly larger in endometrial cancers, with a
median length over 1.0 µm [Arnett-Mansfield et al., 2007].
PR isoform composition in foci can be aberrant in cancers,
with PRA seldom being found in foci, in contrast to PRB
[Arnett-Mansfield et al., 2004], and foci in endometrial
cancer are associated with clinical grade [Arnett-Mansfield
et al., 2004].The differences in PR foci in normal and
cancer tissues suggest that PR foci in cancers may
contain different and/or larger numbers of coregulator
proteins, and may be functionally different.The link
between PR foci in cancers and clinical features suggest
that these observations have physiological and clinical
relevance.
The role of PR coregulators in regulating
progesterone action in human tissues
It is fascinating to realize that what can be seen at the
microscopic level as PR foci, in fact represents active
and highly mobile PR molecules engaged in
transcriptional regulation of target genes and recruiting
key coregulators to achieve this regulation. Binding of
ligand to PR leads to receptor dimerization,
conformational change, association with specific response
element sequences in proximal and distal regions of target
genes and regulation of transcription.This transcriptional
regulation is a complex multistep process, which involves
the sequential recruitment of a number of primary and
secondary coactivators possessing a range of enzymatic
activities.The complex combinatorial process of
chromatin remodeling, coregulator recruitment and
initiation of transcription by nuclear receptors is now well
characterized and has been described in detail in recent
reviews [Lonard et al., 2007; Lonard and O'Malley, 2007;
Wolf et al., 2008], so only a brief summary is given here.
The ligand-dependent change in PR conformation
promotes recruitment of p160 coactivators
(SRC-1/NCoA-1, SRC-2/GRIP1/TIF2,
SRC-3/AIB1/ACTR/TRAM1/ p/CIP) [Han et al., 2006; Han
et al., 2005; McKenna et al., 1998; Onate et al., 1995],
histone acetylases (including p300/CBP) [McKenna et
al., 1998], DNA helicases (including components of the
SWI/SNF complex) [Vicent et al., 2004], ubiquitin ligases
(such as E6-AP) [Nawaz et al., 1999], methylases
(CARM1) [Lonard and O'Malley, 2007] and the steroid
receptor-specific RNA activator SRA [Lanz et al., 1999].
This brings about histone modification and remodeling of
the local chromatin to allow recruitment and activation of
the RNA polymerase II holocomplex leading to increased
RNA transcription of the target gene [Lonard and
O'Malley, 2007].
More than 300 coregulators have now been described
and more PR-binding coactivators exist than are required
to form a functional PR activation complex. It has been
hypothesized that the specific combination of coactivators
that associate with PR in a given cell is dependent on
their relative abundance, which varies in a tissue-specific
manner [Giangrande et al., 2000; Han et al., 2005; Lonard
et al., 2007]. Moreover, although no study has yet
identified unique coregulators of PRA or PRB, in vitro
evidence suggests that they have different affinities for
a common set of coregulators, resulting in cell
type-specific differences in transcriptional activity [Han
et al., 2006; Molenda-Figueira et al., 2008;Tung et al.,
2006].
Given that PRA and PRB are equivalently expressed in
most human target tissues, yet the effects of progesterone
are highly tissue-specific, it is likely that variations in the
levels of specific PR coregulators with distinct affinities
for the two PR isoforms may provide a mechanism by
which a functional predominance of PRA or PRB is
achieved. It is clear that the level of coregulator
expression is critical in determining the overall
transcriptional activity of PR in target tissues, and there
is now abundant evidence linking aberrant coregulator
expression or activity to diseases including cancer [Lanz
et al., 2008].The identification of aberrant coregulator
expression in cancers provides support for the view that
recruitment of coregulators to PR is altered in cancers,
as evidenced by aberrant PR foci observed in cancers
compared to normal tissues. Although the corepressors
N-CoR and SMRT play no role in normal PR physiology,
they have been found to associate with PR and ER when
bound to the mixed antagonists RU38486 and tamoxifen,
respectively, to suppress the agonist effects of these
compounds [Jackson et al., 1997; Smith et al., 1997].
Decreased expression of these corepressors may
contribute to the tamoxifen resistance phenotype
[Lavinsky et al., 1998; Smith et al., 1997]. It has also been
suggested that differences in PR coregulator expression
levels might account for variations in hormone
responsiveness seen in the population [Gao et al., 2005].
In summary, variation in the level of both coactivators
and corepressors of PR is likely to represent an important
mechanism controlling responsiveness to progesterone
in normal and malignant tissues in the human.Therefore,
determining the tissue distribution and regulation of
coregulator expression in the human is likely to be an
important key to understanding the diversity of
progesterone effects.
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animal tissues
Much of the current understanding about the
tissue-specific functions of PR coactivators has been
derived from their ablation in animals.These studies have
revealed that while some functional redundancy may exist
between the p160 coactivator family members, there is
a critical requirement for specific isoforms in progesterone
target tissues. For example, disruption of the SRC-3 gene
in mice causes severe growth and reproductive defects,
including attenuation of mammary ductal side-branching
[Xu et al., 2000], a developmental process shown to be
driven by progesterone [Conneely et al., 2007; Lydon et
al., 1995]. SRC-1 null mice also display specific
aberrations, some of which are distinct from those
observed in the SRC-3 knock-out model, such as
attenuated decidual response in the uterus and elevated
expression of SRC-2 [Xu et al., 1998]. Mice in which
SRC-2 ablation is specifically directed to progesterone
target cells reveal an essential role for this coactivator in
mediating embryo implantation.These animals are
infertile, lack a uterine decidual response and display
markedly attenuated ductal side-branching [Mukherjee
et al., 2006b]. In a study comparing the tissue-specific
requirements for SRC-1 and SRC-3 for progesterone
signaling, a PR activity indicator (PRAI) mouse model
crossed into either an SRC-1 or SRC-3 null background
confirmed that SRC-3 is the primary p160 coactivator for
PR in the mammary gland, whereas the role of SRC-1 in
modulating progesterone action is most evident in the
uterus [Han et al., 2006].There is clear evidence from
combined studies of SRC-1 and SRC-2 null mice,
displaying overlapping defects in uterine decidual
response [Jeong et al., 2007], that these two coactivators
function cooperatively to facilitate progesterone action in
this tissue. In summary, these knock-out studies
demonstrate that the three SRC isoforms play
complementary tissue-specific roles in mediating
progesterone action in the rodent, with SRC-1 and SRC-2
both playing essential roles in the uterus and SRC-3 being
critical in the mammary gland. Animal model studies
analysing the role of numerous other PR coregulators in
reproductive function have previously been reviewed [Gao
and Nawaz, 2002; Li et al., 2004; Rowan and O'Malley,
2000].
Expression of PR coregulators in normal
progesterone target tissues in the human
Despite the evidence that physiological response to
progesterone in specific target tissues is affected by the
combination and expression levels of PR coregulators,
a comprehensive profile of coregulator expression is
generally unavailable in these tissues in the human.
However, some studies of individual coregulators have
examined their expression in progesterone-responsive
tissues, particularly the mammary gland and reproductive
tissues, and in the case of two PR coregulators SRA
[Lanz et al., 2003] and E6-AP [Ramamoorthy and Nawaz,
2008], wide-ranging surveys of tissue distribution in the
human have been made.The collective findings of these
studies are summarized in Table 1. In some cases,
functional correlates have been sought, such as
fluctuations in coregulator expression during the
menstrual cycle or patterns of expression that overlap
with PR.These will be discussed.We have attempted to
highlight in each case, whether protein or transcript level
has been measured, since levels of or fluctuations in
transcript expression may not always correlate with what
is observed at the protein level.
The expression of p160 steroid receptor coactivators has
been examined in human breast, endometrium, brain and
ovary. Kurebayashi et al [Kurebayashi et al., 2000]
reported RNA transcript expression for all three SRC
isoforms in a small cohort of normal breast tissues. SRC-1
was the most strongly expressed of all SRC coactivators,
showing strong expression in all specimens, whereas
SRC-2 and SRC-3 showed relatively weak expression.
SRC-2 protein is detected in human mammary epithelium
and results of PR staining of adjacent sections, coupled
with evidence from dual detection in mouse tissues,
suggest colocation with PR [Mukherjee et al., 2006a;
Mukherjee et al., 2006b]. A number of investigators have
also reported on SRC expression in the human
endometrium.Transcript expression of all three SRC
isoforms is detected in normal human endometrium
[Kershah et al., 2004;Vienonen et al., 2004] and
expression levels are similar for the three forms [Kershah
et al., 2004]. Protein expression of SRC-1 [Gregory et
al., 2002; Shiozawa et al., 2003], SRC-2 [Gregory et al.,
2002; Mukherjee et al., 2006b] and SRC-3 [Balmer et al.,
2006; Gregory et al., 2002] has also been reported in
glandular epithelium and stroma in the endometrium, and
the study of Gregory et al suggested that although
expression levels were similar, SRC-3 staining was
slightly lower than SRC-1 or SRC-2. Evidence for
fluctuation in SRC expression during the normal menstrual
cycle is conflicting. Shiozawa et al reported higher
expression of SRC-1 protein in the proliferative phase
endometrium [Shiozawa et al., 2003], whereas in another
study SRC-1 RNA expression was found to be
significantly higher at menstruation, compared to either
proliferative or secretory endometrium [Wieser et al.,
2002].The studies of Gregory [Gregory et al., 2002] and
Balmer [Balmer et al., 2006] reported no change in SRC-1
protein through the cycle, but observed an increase in
SRC-3 in secretory phase endometrium. In summary,
while there is suggestive evidence that coactivator
expression in the endometrium may fluctuate during the
menstrual cycle to modulate hormonal response, more
studies are required to clarify the current observations.
Transcripts for SRC1-3 have also been detected in
surface epithelium of the normal ovary [Evangelou et al.,
2003] and whole normal ovary samples [Hussein-Fikret
and Fuller, 2005]. SRC expression is also detectable in
the normal brain: immunoblot analysis of a small cohort
of normal brain samples revealed consistent expression
of SRC-1 and SRC-2, but SRC-3 was absent in all
samples [Carroll et al., 2000]. Although limited information
is available on the specificity of SRC expression in the
normal human brain, studies in rodents have revealed
that SRC-1 protein is present in regions of the
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Review Progesterone action in human tissuesTable 1. : Reported patterns of PR coregulator expression in human tissues. The findings of studies reporting expression of known PR
coregulators at the transcript or protein level in human tissues are summarised.
hypothalamus that are functionally relevant to
progesterone action in the brain, and cells that express
PR generally also express SRC-1 and CBP, as detected
by dual immunofluorescence [Tetel et al., 2007].
Consistent with its role as a fundamental nuclear receptor
coactivator, p300/CBP is detectable in all progesterone
target tissues examined and there is not strong evidence
for fluctuations in expression in normal tissues. CBP
transcripts are detected in the normal breast [Kurebayashi
et al., 2000] and both CBP and p300 transcripts have
been detected in the endometrium and myometrium
[Vienonen et al., 2004]. Shiozawa reported abundant
expression of p300/CBP protein in normal endometrium,
with slightly higher expression observed in proliferative
endometrium [Shiozawa et al., 2003].
SRA, a PR coactivator which acts as an RNA, exhibits
relatively high expression levels in the human pituitary
gland, adrenal gland and liver, and relatively low levels
of expression in the breast, ovaries, uterus and prostate
[Lanz et al., 2003].The coregulator E6-AP functions as
a coactivator to several nuclear receptors including PR,
ER and AR, via its role in the ubiquitin-proteasome
pathway, where it is required for the degradation and
proper turnover of numerous nuclear hormone receptors
[Gao et al., 2005]. E6-AP also directs turnover of other
PR-associated coactivators, such as AIB-1/SRC-3 [Mani
et al., 2006], suggesting that E6-AP may play an important
role in clearing the transcriptional coregulatory complex
from a promoter region to allow for the subsequent
interaction of activated receptor with a newly-assembled
coactivator complex.The finding that the hect domain in
E6-AP, which is involved in recruitment of ubiquitin
conjugating enzymes, UbcH7 and UbcH8, is not essential
for in vitro coactivation of PR [Nawaz et al., 1999],
suggests that E6-AP also functions as a coactivator via
mechanisms that are independent of its ubiquitin ligase
function. Relative expression of E6-AP RNA transcripts
in a variety of human tissues was found to be greatest in
the lymph node, pineal gland and bladder, moderate in
the placenta, uterus, brain, bone and liver, and lowest in
the mammary gland, ovary, adrenal gland and blood
[Ramamoorthy and Nawaz, 2008].
Transcripts for the PR corepressors N-CoR and SMRT
are detectable in mammary gland [Kurebayashi et al.,
2000], endometrium and myometrium [Vienonen et al.,
2004]. N-CoR was the predominant transcript detected
in all three tissue types. As these observations were made
in small cohorts of normal tissues collected from clinical
specimens, where normal breast samples were obtained
from breast cancer specimens by resection of adjacent
normal tissue and normal endometrial tissue was derived
from hysterectomy samples, it is debatable how normal
these tissues may be considered to be, and additional
studies in larger cohorts of validated normal tissues would
be required to confirm these observations.
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progression and cancer
There is now strong evidence that altered coregulator
expression or activity occurs in a number of human
pathologies, including cancers in progesterone target
tissues [Lanz et al., 2008].The general trend for PR
coactivators is to be overexpressed and amplified in
cancers, suggesting that increased availability of these
proteins may enhance PR activity in tissues such as the
breast, where it is known to play a role in cancer
development. Overexpression in cancers of coregulators
that are not normally abundant in a particular normal
tissue, for example the breast or uterus, may allow PR
to complex with coregulators in cancer tissues that it
would not associate with in the corresponding normal
tissue, and lead to changed target gene selection.
Among the PR coregulators known to be associated with
malignancy, SRC-3 is the best characterized. Initially
identified as Amplified In Breast cancer-1 (AIB-1), SRC-3
is often highly expressed and amplified in primary human
breast cancers [Anzick et al., 1997] and amplification is
correlated with elevated protein level [List et al., 2001].
A screen of 105 unselected specimens of primary breast
cancer revealed SRC-3 amplification in approximately
10% of primary tumors and this amplification was
correlated with elevated transcript expression [Anzick et
al., 1997]. In addition, elevated SRC-3 expression relative
to normal mammary epithelium was detected in 58% of
tumors in which no amplification was detected [Anzick et
al., 1997], indicating that overexpression of SRC-3 by
mechanisms other than amplification also occurs
frequently in human breast cancers. Bautista et al
[Bautista et al., 1998] demonstrated increased SRC-3
copy number in 4.8% of breast tumors and 7.4% of
ovarian tumors and amplification in breast cancers was
positively correlated with ER and PR. Increased SRC-3
transcript [Kershah et al., 2004] and protein [Balmer et
al., 2006] expression was also reported in endometrial
cancers and was correlated with ER and PR positivity
[Balmer et al., 2006].
Overexpression of SRC-2 and SRC-3 has also been
reported in endometrial, prostate and brain cancers
[Carroll et al., 2000; Kershah et al., 2004; Lanz et al.,
2008], supporting their role in enhanced hormone
responsiveness in these malignancies. Gregory et al
[Gregory et al., 2002] showed an increased level of
expression of SRC-2 and SRC-3 in the endometrium of
women with polycystic ovarian syndrome, a condition
known to be associated with a higher risk of endometrial
cancer. Elevated expression of SRC-2 was reported in
meningiomas, compared to normal brain, and expression
was correlated with PR expression [Carroll et al., 2000;
Lanz et al., 2008].
Altered expression of coregulators that can impact on
SRC function has also been reported.The
magnesium-dependent protein phosphatase PPM1D has
been reported to enhance the intrinsic activity of p160
coactivators and to promote interaction between PR and
SRC-1 [Proia et al., 2006]. PPM1D, which enhanced PR
activity in vitro [Proia et al., 2006], was amplified and
overexpressed in breast cancer cell lines and primary
breast cancers [Bulavin et al., 2002; Li et al., 2002]. As
described above, the ubiquitin ligase function of E6-AP
is required for proper turnover of coactivators, as well as
nuclear receptors. E6-AP was lower in invasive breast
cancer than in adjacent normal mammary tissue or ductal
carcinoma in situ (DCIS) [Gao et al., 2005], suggesting
that reduced ubiquitin ligase activity may contribute to
the elevation in p160 coactivator levels often observed
in breast cancers.The expression of E6-AP in DCIS was
not different from normal tissue, suggesting that the
downregulation of E6-AP protein is a relatively late event
in the development of cancer and is associated with the
invasive phenotype [Gao et al., 2005]. Consistent with its
role in ER and PR turnover, E6-AP protein level was
inversely correlated with expression of ERα, suggesting
that loss of this coregulator may augment hormone
signaling in breast cancers.
In a survey of several cancer types, SRA was
overexpressed in over 90% of ovarian primary tumor
samples, 100% of uterine samples, and 90% of breast
tumors, compared to increased expression in fewer than
35% of tumors of the pancreas and kidney, suggesting
that the upregulation of SRA was specific for
hormone-dependent malignancies [Lanz et al., 1999].
This is in contrast to the relatively lower expression of
SRA in normal hormone-responsive tissues.
Overexpression of SRA in transgenic mice resulted in
precocious lobular-alveolar development of the mammary
gland during pregnancy, thus supporting the assertion
that overexpression of SRA in the breast may enhance
progesterone action and in this way could contribute to
breast cancer development [Lanz et al., 2003].
Overexpression of transcripts for the corepressors N-CoR
and SMRT has been reported in breast [Kurebayashi et
al., 2000] and endometrial cancers [Kershah et al., 2004].
Both of these studies are relatively preliminary and the
impact of transcript overexpression on protein levels has
not been determined. Moreover, since these corepressors
only affect PR action in the context of mixed antagonists,
their overexpression in progesterone target tissues is
unlikely to play a role in progesterone-related breast
cancer etiology.
In summary, the studies discussed suggest that
amplification and/or altered expression of PR coregulators
is a relatively common event in hormone-dependent
malignancies, which appears likely to have functional
consequences for progesterone signaling in those tissues,
particularly if elevated abundance of coregulators
enhances steroid responsiveness in cancer tissues.
Summary and conclusion
When bound to progesterone, PR activates target gene
transcription in a diverse range of target tissues such as
the breast, uterus, brain, central nervous and
cardiovascular systems.The effects of progesterone on
these target tissues are diverse, and the evidence to date
supports the view that coregulators play a critical role in
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response to progesterone, and contribute to the
expression of a diverse subset of progesterone-regulated
genes and specificity of progesterone action in target
tissues.
The pool of coregulators that are able to associate with
PR, and the complex series of steps involved in receptor
activation, coregulator association and ultimately
transcriptional activation have now been defined by
elegant in vitro studies [Lonard et al., 2007; Lonard and
O'Malley, 2007]. However, it is clear that there is a surplus
of potential PR interactors, and the nature of endogenous
PR-coregulator complexes that actually form in true target
tissues has not been explored. Delineation of the role of
coregulators in the specificity of PR action in target tissues
will require demonstrating a functional association
between the progesterone receptor and its coregulators
in human tissues and identification of the PR coregulators
required for progesterone action in human physiology.
Although the expression and role of PR coregulators has
been extensively studied in vitro and in animal models,
it has become evident that few studies have looked
comprehensively at PR coregulator levels and function
in human tissues, making it difficult to assess whether
the differences in progesterone action can be attributed
to specific coregulator interactions with PR. Nevertheless,
disparity in PR coregulator expression in various human
tissues, such as in the endometrium throughout the
different phases of the menstrual cycle, suggest that PR
coregulators do play an important role in regulating the
tissue-specific response to progesterone.
Demonstration of the co-location of PR and coregulators
by in situ methods such as immunofluorescence in target
tissues is an essential first step in demonstrating a
functional association that potentially contributes to the
specificity of PR action.Very few studies in human tissues
have explored co-location of PR and coregulators, and
of those that have, none have distinguished between
expression of the two PR isoforms and the differential
coregulator affinities of PRA and PRB. As co-location is
a correlative measure of association, direct measurement
of PR-coregulator association, ideally performed on
primary human cells, may allow for the identification of
coregulatory proteins existing in a complex with the PR,
providing support for a functional association. Such
studies would also contribute to the identification of PR
coregulators that are required for progesterone action in
the various cell types in which this receptor is active in
normal physiology.
It is essential to identify PR coregulators required for PR
to move into nuclear foci, as these coregulators are likely
to play a direct role in regulating the specific effects of
progesterone in normal tissues and in cancers.The
aberrant formation of PR foci in cancers suggests that
PR forms complexes with different and/or larger numbers
of coregulatory proteins in these tissues, potentially
leading to functionally different PR foci in normal and
malignant cells. An analysis of PR coregulators involved
in PR foci formation is required to identify PR coregulators
directly involved in modulating progesterone effects in
normal tissues and cancers.
A significant challenge in identifying coregulators required
for progesterone action arises from the fact that nuclear
receptors are highly related, sharing the same structural
features and utilizing a common pool of coregulator
partners to regulate transcription. All coregulators that
have been demonstrated to interact with PR, also interact
with numerous other nuclear receptors such as ER and
AR, and interact with unrelated transcription factors.
Furthermore, evidence suggests that coregulators can
control cellular functions outside of the nucleus such as
mRNA translation, mitochondrial function, and motility
[Dawson et al., 1996].
In summary, it has become clear that studies of
coregulators, their interaction with the PR, and the
downstream effects of such interactions in progesterone
target tissues in the human, are still in their infancy.
Further studies are required to uncover the role of PR
coregulators in human tissues and the impact of variation
in their level of expression on progesterone action in
human cells and tissues.
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